Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia and experience higher rates of relapse and treatment toxicity. In recent decades, new therapies have improved outcomes for the general population, but outcomes for children with Down syndrome have lagged and have not been reported for contemporary treatment regimens.
Takeda Oncology presented efficacy and safety data from the phase III PhALLCON trial studying Iclusig (ponatinib) in adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia during a virtual American Society of Clinical Oncology’s Plenary Series Program Feb. 15.
